According to our results, the proportion of CTAs expression in UPS was the highest (76%), and PRAME was the predominant one (47.62%), suggesting that PRAME may be a therapeutic target for UPS. The gene discussed is PRAME; the disease is undifferentiated pleomorphic sarcoma.